GlaxoSmithKline LLC on Thursday filed a second lawsuit in federal court in Philadelphia against Teva Pharmaceuticals USA Inc. over a generic version of Wellbutrin XL, this time alleging Teva’s false advertising that its generic was comparable to the antidepressant cost GSK’s business partner millions.

GlaxoSmithKline lodged its initial lawsuit against Teva in 2013, accusing the generic drug seller of lying to customers about the drug’s quality and unfairly cutting into its sales of the antidepressant, court records show. On Thursday, GSK issued a second complaint, this time seeking damages for Valeant Pharmaceuticals International Inc., the brand-name drug’s manufacturer.

Valeant, previously known as Biovail Corp., is owed “millions” on lost sales of Wellbutrin XL thanks to Teva’s alleged lies about the drug’s ability to replace the brand-name antidepressant and its refusal to pull the generic from the market even when there were signs something was wrong, according to the suit.

“Biovail and GSK each derived revenues from net sales of Wellbutrin XL,” the pharmaceuticals company said in its lawsuit. “Because of Teva’s false advertising, which decreased the amount of Wellbutrin XL that GSK sold, Biovail lost millions of dollars.” GSK is represented by Leslie E. John, Stephen J. Kastenberg, Jason A. Leckerman and Marcel S. Pratt of Ballard Spahr LLP.

Related Practices

Health Care
Patents